A practical reference on counterion: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
== Dextran nanoparticles == Dextran nanoparticles are 1-100 nm sized particles with drug encapsulation capability. The high surface area of these nanoparticles allows more drugs to be loaded and encapsulated, leading to higher drug concentrations at the target site. The small size of these particles also encourages cellular uptake, which makes dextran nanoparticles a potential effective drug delivery system for targeting tumor cells.
Clinical attachment level (CAL) is a clinical measurement used in periodontology to determine the position of the periodontal attachment relative to a fixed anatomical landmark on the tooth, usually the cementoenamel junction (CEJ). It is a fundamental parameter for assessing the severity and progression of periodontal disease, monitoring treatment outcomes, and evaluating changes in periodontal support over time. Clinical attachment loss refers to the pathological loss of periodontal attachment, which is quantified by the clinical attachment level. Unlike probing depth alone, clinical attachment level accounts for changes in the position of the gingival margin, providing a more accurate assessment of periodontal attachment loss.
Sugar used in commercial chocolate milk serves as a preservative, and the energy from the sugar also makes it a convenience food. It can also be made at home by blending milk with cocoa powder and a sweetener (such as sugar or a sugar substitute), melted chocolate, chocolate syrup, or a pre-made powdered chocolate milk mix. Other ingredients, such as starch, salt, carrageenan, vanilla, or artificial flavoring are sometimes added. To add nutritional value to the product, sometimes some minerals like zinc oxide or iron are added. In New York City, school food officials report that nearly 60 percent of the 100 million cartons served each year contain fat-free chocolate milk.
The Maastricht Treaty renamed the EEC as the "European Union", and expanded its powers to include a social chapter, set up a European Exchange Rate Mechanism, and limit government spending. The UK initially opted out of the social provisions, and then monetary union after Black Wednesday in September 1992 where speculators bet against the British currency. Sweden, Finland and Austria joined in 1995, but Norway again chose not to do so after its 1994 referendum, instead remaining part of the European Free Trade Area (EFTA) and thus the European Economic Area (EEA), abiding by most EU law but without any voting rights. At the Treaty of Amsterdam, with a new Labour government, the UK joined the social chapter. A newly confident EU then sought to expand. First, the Treaty of Nice made voting weight more proportionate to population. Second, the Euro currency went into circulation in 2002. Third came the accession of Malta, Cyprus, Slovenia, Poland, the Czech Republic, Slovakia, Hungary, Latvia, Estonia, and Lithuania. Fourth, in 2005 a Treaty establishing a Constitution for Europe was proposed. This proposed "constitution" was largely symbolic, but was rejected by referendums in France and the Netherlands. Most of its technical provisions were inserted into the Treaty of Lisbon, without the emotive symbols of federalism or the word "constitution". In the same year, Bulgaria and Romania joined. During the subprime mortgage crisis and the 2008 financial crisis, European banks that were invested in derivatives were put under severe pressure.
Sources: en.wikipedia.org
Wills Professor of Physics, University of Bristol. For services to Physics. Professor Henry John Evans. For services to Medical Research. James Stuart Fair, Chairman, Dundee Teaching Hospitals NHS Trust. For services to Health Care. Jonathan Farquharson, lately Legal Commissioner, Charity Commission. Thomas Hugh Francis Farrell, , Pro-Chancellor and Chairman of Council, University of Hull. For services to Higher Education. David Geoffrey Nigel Filkin, Secretary, Association of District Councils. For services to Local Government. Stanley Fishman, President, Cinema Exhibitors' Association. For services to the Film Industry. Frederick Forsyth, Writer. For services to Literature. Michael John Ernest Frye, Chief Executive, B. Elliott plc. For services to Business. Professor Charles Albert Eric Goodhart, Professor of Banking and Finance, London School of Economics. For services to Monetary Economics. Peter James Grant, Chairman, Highlands and Islands Airports Ltd. For services to Industry. Paul Frederick Gribble. For political service. Ewan William Harper. For services to the Church of England. Derek James Harrington, Deputy Chairman and Chief Executive, Port of Felixstowe Ltd., and Director, Hutchison International Port Holdings. For services to the Ports Industry. Peregrine Andrew Morny Cavendish, Marquess of Hartington, lately Senior Steward of the Jockey Club and Chairman, British Horse Racing Board. For services to Horse Racing. David Hewitt. For services to the Community. Pamela Jean Hibbs, , Chief Nurse and Director of Quality Assurance, Royal Hospitals NHS Trust, London.
Social defeat Likewise, the hypothalamus has a role in social defeat: nuclei in medial zone are also mobilized during an encounter with an aggressive conspecific. The defeated animal has an increase in Fos levels in sexually dimorphic structures, such as the medial pre-optic nucleus, the ventrolateral part of ventromedial nucleus, and the ventral premammilary nucleus. Such structures are important in other social behaviors, such as sexual and aggressive behaviors. Moreover, the premammillary nucleus also is mobilized, the dorsomedial part but not the ventrolateral part. Lesions in this nucleus abolish passive defensive behavior, like freezing and the "on-the-back" posture.
1RAR trained in Kenya from December 1943 to September 1944, when it transferred to Ceylon and became part of the 22nd (East Africa) Infantry Brigade alongside the 1st KAR and the 3rd Northern Rhodesia Regiment. In December 1944, after three months' training for jungle warfare, 1RAR and the other two components of the brigade joined the Burma Campaign at Chittagong under the command of the 15th Indian Corps. The brigade spent about three months supporting the 25th Indian Division in north-western Burma, advancing through the Mayu peninsula during January 1945 and taking part in the latter stages of the Battle of Ramree Island, landing on the island on 14 February. 1RAR fortified positions at Myinbin, Kyaukkale and Mayin but did not contact Japanese forces. A widespread belief developed among Japanese troops in Burma that the British Army's African soldiers were cannibals, partly because of deliberate disinformation spread by the black troops themselves as they travelled around the country. While entirely unfounded, the notion "that we Africans eat people", as one RAR soldier put it, had a fearsome psychological effect; men of 1RAR reported Japanese soldiers picking up their comrades' bodies in the midst of battle and running away. In March 1945 the 22nd Brigade was ordered south to Dalaba where it became part of the 82nd (West Africa) Division, which had been tasked with clearing the Taungup area of Japanese troops.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.